Precision Medicine and Immuno-Oncology China Summit 2017

 

2017中国精准医学与肿瘤免疫治疗国际峰会

攻克癌症成为各国精准医疗计划的中心。癌症的发病率增加以及医疗开支不上升推动市场的增长。根据美国市场研究公司markets and markets发布报告称,全球癌症免疫治疗市场的规模将从2016年的619亿美元,增长到2021年的1193.9亿美元,复合年增长率达14.0%。作为癌症免疫疗法中的主力军,PD-L1/PD-1抗体已经展现了良好的市场前景。另外,细胞治疗也备受关注。数据显示,截至到2016年6月,全球正在进行的CAR-T临床试验有173项,中国开展的CAR-T临床试验数量位居全球第二,共计30项,涉及24个靶点,仅次于美国。专家认为,随着基因诊断、免疫技术的不断进步,“基于细胞免疫治疗的联合疗法”可能彻底改变癌症治疗,是具有重大投资价值的人类突破性技术。

基于以上背景,在美国华人生物医药科技协会(CBA)和美中协会大费城分会(SAPA-GP)的大力支持下,2017中国精准医学与免疫肿瘤治疗峰会(PMIO将与4月在上海召开,本次大会以精准医学为背景和切入点,将关注精准医疗、肿瘤免疫、分子诊断、生物药等前沿技术和最新发展,大会旨在促进精准医学从实验室到临床,从基因检测技术应用到个体化用药的转化,同时为国内外专家高端交流,产业与资本对接搭建平台。大会将邀请300+来自政府监管机构、行业协会、医院、科研院校、医药公司、生物技术公司、CRO公司、大数据解决方案提供商、投资机构、律所、咨询机构等高层代表共同探讨国内外从肿瘤的精准治疗、干细胞治疗到联合治疗的临床最佳实践,介绍国内外生物样本库建设情况和精准医学中的应用,交流国内外知名药厂在精准医药研发进展和取得的成果,展示前沿生物技术与应用,共商产学研合作模式。我们诚挚地邀请您出席本次论坛,共商中国精准医疗的发展的方向和宏伟蓝图。

有关更多详细信息,请登录网址www.pmio-china.com或联系会务组8621-3112-3968,或发送邮件至[email protected]

 

Precision Medicine and Immuno-Oncology China Summit 2017

Curing cancers have come become the core part of PMI for different countries due to the rising incidence of cancer and associated medical expenditure. Based on authoritative report, the global market size for cancer immunotherapy will grow to roughly USD 100 billion in 2021 from USD 620 billion in 2016 with 14% CAGR. PD-L1/PD-1 antibody has demonstrated good market prospect. Besides, cellular therapy has attracted global attention. Based on statistics, there’re 173 ongoing CAR-T clinical trials in the world and China ranks 2nd next to US with 30 clinical trials and 24 targets. Experts think with advancements in gene diagnostics and immunotherapy, cell based combination therapy could be human ground breaking technology to completely change the way of curing cancers.

Under this background and co-organized by Chinese Biopharmaceutical Association (CBA) and SAPA-GP, Precision Medicine and Immuno-oncology China 2017 will be convened in April in Shanghai. With the background of precision medicine, the theme will be centered on recent advancement and application of precision medicine, immunotherapy, biologics development and molecular diagnostics. The show is intended to promote the translation of precision medicine from bench to beside and from application of genetic testing to personalized medicine. Meantime, we are building a premier networking platform for industry companies and capitals to work together in China’s precision medicine industry. The show will attract 300+ delegates from regulatory body, industry association, pharma, biotech companies, CROs, hospitals, research institutes, biobanks, solutions providers to explore best clinical practice of precision therapy, stem cell and combination therapy, exchange recent advancement of precision medicine R&D in big pharma, showcase frontier technology and applications, and explore collaboration between industry and academia. We cordially invite you to attend this international summit and discuss China’s promising future of precision medicine.

For more information, please visit www.pmio-china.com, or call the organizing committee at 8621-3112-3968, or send your enquiries to [email protected].

 

2017-03-31T00:42:57+00:00